All In Biotech

Drug Trial Radar · NCT04576156

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 327 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

327

Actual

Start

Apr 12, 2021

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Geron CorporationIndustry
Sponsor type
Industry
First posted
Oct 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.

Conditions

  • Myelofibrosis

Interventions

  • ImetelstatDrug

    Imetelstat sodium will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.

  • Best Available Therapy (BAT)Drug

    Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Baseline (Day 1) until End of Study (EOS) (approximately 3 years )]

Locations

144 sites in 26 countries. Site status is shown where the registry gives one.

  • University of California-San Diego/Moores UCSD Cancer Center

    La Jolla, California

  • UCLA David Geffen School of Medicine

    Los Angeles, California

  • Smilow Cancer Center at YNHH

    New Haven, Connecticut

  • BRCR Medical Center Inc

    Plantation, Florida

  • University of South Florida

    Tampa, Florida

  • Norton Cancer Institute

    Louisville, Kentucky

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Gabrail Cancer Center

    Canton, Ohio

  • Prairie Lakes Health Care System, Inc.

    Watertown, South Dakota

  • The University of Texas MD

    Houston, Texas

  • Northwest Medical Specialties PLLC

    Seattle, Washington

  • Sanatorio Allende

    Córdoba, Argentina

  • Hospital Aleman

    Ciudad de Buenos Aires, Buenos Aires, Argentina

  • Sanatorio de la Mujer

    Rosario, Santa Fe Province, Argentina

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Epworth Healthcare

    Richmond, Victoria, Australia

  • Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhügel

    Wein, Burgenland, Austria

  • Krankenhaus der Elisabethinen

    Linz, Upper Austria, Austria

  • Kepler Universitätsklinikum Gm

    Linz, Upper Austria, Austria

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Upper Austria, Austria

  • Universitair Ziekenhuis Brussel - Myeloom Centrum Brussel (MCB)

    Jette, Belgium

  • AZ Klina

    Antwerp, Antwerpen, Belgium

  • UZ Antwerpen

    Edegem, Antwerpen, Belgium

  • Centre Hospitalier de Jolimont

    Haine-Saint-Paul, Hainaut, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Oost-Vlaanderen, Belgium

  • CEPON Centro de Pesquisas Oncologicas SC

    Florianópolis, Brazil

  • Hospital A.C.Camargo Cancer Center - Clinical Oncology

    São Paulo, Brazil

  • Centro de oncologia Leonardo da Vinci

    Fortaleza, Ceará, Brazil

  • Hospital das Clínicas UFG

    Goiânia, Goiás, Brazil

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil

  • Hospital de Clinicas de Porto Alegre - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa LTDA

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Israelita Albert Einstein

    São Paulo, São Paulo, Brazil

  • Fundacao Doutor Amaral Carvalho / Hospital Amaral Carvalho

    São Paulo, São Paulo, Brazil

  • UMBAL Sveti Georgi

    Plovdiv, Plovdiv, Bulgaria

  • Specialized Hospital for Active Therapy of Hematological dis

    Sofia, Sofia, Bulgaria

  • Hospital Pablo Tobon Uribe

    Antioquia, Colombia

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.